Journal of Diabetes最新文献

{"title":"Commentary on the T1D Exchange Quality Improvement Collaborative Learning Session November 2025 Abstracts","authors":"Stephanie S. Crossen, Nicole Rioles, Claire Rainey, Halis K. Akturk","doi":"10.1111/1753-0407.70214","DOIUrl":"10.1111/1753-0407.70214","url":null,"abstract":"<p>The T1D Exchange Quality Improvement Collaborative (T1DX-QI) is a network of 63 adult and pediatric diabetes centers [<span>1, 2</span>] which collectively care for more than 150,000 people with diabetes (PWD) across the United States. Member centers map and report their data on diabetes care and outcomes and engage in quality improvement projects with the shared goal of improving health outcomes for all PWD. Each November, the group hosts its annual Learning Session to share lessons learned and facilitate ongoing collaboration on key topics of interest. This year’s Learning Session touched on a broad range of topics, from diabetes technology to mental health, sick day protocols to transitions of care, and reflected new emphases within the collaborative on screening and early identification of type 1 diabetes, and on optimizing care for type 2 diabetes in pediatric populations.</p><p>Over a dozen abstracts focused on improving timing or equity in the adoption of diabetes technology. Several centers initially deployed surveys to patients [<span>3, 4</span>] or clinicians [<span>5, 6</span>] to target their technology-related QI efforts within a complex system. Clinicians involved in a multi-center QI project to accelerate automated insulin delivery (AID) adoption identified insurance coverage, standardized clinic processes, patient and clinician education about AID, and communication with pharmacies and DME suppliers as key drivers and potential barriers to early AID access [<span>7, 8</span>]. QI initiatives focused on continuous glucose monitoring (CGM), in turn, cited the importance of addressing clinician bias, improving device accessibility, and developing standardized education [<span>9, 10</span>]. Many centers described multi-pronged interventions that expanded access to multidisciplinary visits or classes to successfully reduce wait times [<span>11-13</span>] or increase overall uptake of technology [<span>9, 14, 15</span>].</p><p>Transition of care from pediatric to adult endocrinology also continued to be a focus at this year's learning session. Several projects found that the success of new electronic health record (EHR) or educational tools to aid in transition-of-care planning hinged on clinician time and awareness [<span>16, 17</span>] and that even with standardized questionnaires, topics like substance use, reproductive health, and insurance navigation were rarely discussed by pediatric clinicians [<span>18</span>]. However, embedded EHR transition tools were used successfully at several centers [<span>19, 20</span>] and a multidisciplinary approach to transition coordination was found to improve the documentation of transition plans for adolescents with diabetes [<span>19</span>] and to reduce the wait time between pediatric and adult care [<span>21</span>].</p><p>Screening for mental health concerns, social drivers of health, and comorbid medical conditions also featured prominently. Several abstracts described efforts to imp","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Negative Pressure Therapy in Diabetic Foot Ulcer: A Meta-Analysis","authors":"Hai Du,&nbsp;Tao Jiang,&nbsp;Renqun Mao,&nbsp;Xiaofan Yang,&nbsp;Zhenbing Chen","doi":"10.1111/1753-0407.70226","DOIUrl":"10.1111/1753-0407.70226","url":null,"abstract":"<p>Diabetic foot ulcer (DFU) is a severe complication, often leading to amputation. Negative pressure wound therapy (NPWT) is an advanced treatment option requiring further consolidated evidence. This study evaluated the effectiveness and safety of NPWT versus conventional wound care for DFU, focusing on wound healing, amputation prevention, and adverse events (AEs). We systematically searched PubMed, Cochrane Library, Embase, and Web of Science for randomized controlled trials (RCTs) from inception until October 2025. Twenty-three RCTs involving 2086 participants were included. Two reviewers independently selected studies. Outcomes included wound healing rate, ulcer area reduction, amputation rate, and adverse events. Pooled odds ratios (OR) and standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using random-effects models. NPWT significantly improved the wound healing rate (OR 4.48, 95% CI 2.58–7.77), led to a greater reduction in ulcer area (SMD 1.26, 95% CI 0.70–1.82), and substantially lowered amputation risk (OR 0.35, 95% CI 0.19–0.64) compared to conventional care. No significant difference was found in adverse events (OR 0.98, 95% CI 0.56–1.71). Subgroup analyses confirmed benefits across ages, follow-up durations, and control dressings. The healing benefit was most pronounced in less severe ulcers (Wagner grade &lt; 2), while amputation protection was consistent across severities. NPWT is an effective and safe strategy for DFU, significantly accelerating wound healing and reducing amputation risk, supporting its integration as a cornerstone adjunctive therapy.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Socioeconomic Status and the Prevalence of Metabolic Diseases: A Nationwide Cross-Sectional Study in China","authors":"Minghan Zhang,&nbsp;Junru Fan,&nbsp;Qiuyu Cao,&nbsp;Ruizhi Zheng,&nbsp;Yu Xu,&nbsp;Min Xu,&nbsp;Feixia Shen,&nbsp;Xuejiang Gu,&nbsp;Yiming Mu,&nbsp;Lulu Chen,&nbsp;Tianshu Zeng,&nbsp;Lixin Shi,&nbsp;Qing Su,&nbsp;Xuefeng Yu,&nbsp;Li Yan,&nbsp;Guijun Qin,&nbsp;Qin Wan,&nbsp;Gang Chen,&nbsp;Xulei Tang,&nbsp;Zhengnan Gao,&nbsp;Ruying Hu,&nbsp;Zuojie Luo,&nbsp;Yingfen Qin,&nbsp;Li Chen,&nbsp;Xinguo Hou,&nbsp;Yanan Huo,&nbsp;Qiang Li,&nbsp;Guixia Wang,&nbsp;Yinfei Zhang,&nbsp;Chao Liu,&nbsp;Youmin Wang,&nbsp;Shengli Wu,&nbsp;Tao Yang,&nbsp;Huacong Deng,&nbsp;Jiajun Zhao,&nbsp;Guang Ning,&nbsp;Jieli Lu,&nbsp;Weiqing Wang,&nbsp;Yufang Bi,&nbsp;Yuhong Chen,&nbsp;the 4C Study Group","doi":"10.1111/1753-0407.70222","DOIUrl":"10.1111/1753-0407.70222","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metabolic diseases remain a fast-growing global health burden. Besides other known factors, socioeconomic status (SES) has been recognized as a key determinant of metabolic health. This study aimed to investigate the association between SES and the prevalence of metabolic diseases in the Chinese population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed data from a nationwide community-based cross-sectional study in China. SES was derived to a composite score (range 0–3) using three indicators (educational attainment, living conditions, and marital status), with higher scores indicating better SES. Chronic diseases were diagnosed through biochemical testing and clinical assessments. Logistic regression models were applied to estimate associations between SES scores and metabolic diseases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 201 532 participants, the lowest SES group had 87.1% higher odds of metabolic diseases than the highest SES group (odds ratio [OR] = 1.871, 95% confidence interval [CI]: 1.739, 2.016). One-point decrease in SES score was associated with increased prevalence of hypertension (OR = 1.096, 95% CI: 1.080, 1.113) and obesity (OR = 1.112, 95% CI: 1.091, 1.134). In contrast, lower SES scores were linked to a reduced prevalence of dyslipidemia (OR = 0.931, 95% CI: 0.918, 0.945) and diabetes (OR = 0.974, 95% CI: 0.958, 0.990) after adjusting for covariates. We also observed that lower SES scores showed stronger associations with increased prevalence of obesity and hypertension in women but decreased risks of diabetes, dyslipidemia, and obesity in men.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Lower SES was associated with a higher prevalence of hypertension and obesity but a lower prevalence of dyslipidemia and diabetes, with significant gender differences.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13054516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147626744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking Cessation Inertia in Diabetes Care","authors":"Yusuff Adebayo Adebisi,&nbsp;Anoop Misra,&nbsp;Riccardo Polosa","doi":"10.1111/1753-0407.70215","DOIUrl":"10.1111/1753-0407.70215","url":null,"abstract":"&lt;p&gt;Type 2 diabetes (T2D) is one of the most pressing noncommunicable disease challenges globally. In 2022, an estimated 828 million adults were living with diabetes, an increase of approximately 630 million since 1990 [&lt;span&gt;1&lt;/span&gt;]. This rapid rise has unfolded alongside another long-standing epidemic: combustible tobacco use. According to the World Health Organization, approximately 1.3 billion people use tobacco worldwide, and tobacco causes more than 7 million deaths each year, most of them in low- and middle-income countries.&lt;/p&gt;&lt;p&gt;The relationship between tobacco and T2D extends beyond simple co-occurrence. Active smoking is an independent risk factor for incident T2D. Meta-analytic evidence indicates a 37% higher risk among current smokers compared with never smokers, with a clear dose-response gradient [&lt;span&gt;2&lt;/span&gt;]. Unlike type 1 diabetes, which is autoimmune in origin, T2D has a well-established causal link with smoking. The tobacco–T2D nexus therefore represents a preventable and modifiable driver of disease burden.&lt;/p&gt;&lt;p&gt;Modern diabetes care is increasingly structured and metrics-driven. Clinicians routinely monitor glycemia, blood pressure, and lipid levels, stratify cardiovascular risk, and intensify treatment when targets are not achieved [&lt;span&gt;3&lt;/span&gt;]. Yet smoking cessation, despite its well-established role in reducing vascular injury and end-organ damage, remains inconsistently integrated into routine diabetes care. In many settings, smoking status is recorded irregularly, addressed briefly, or deferred to follow-up that never occurs [&lt;span&gt;4&lt;/span&gt;]. As a result, a major modifiable exposure persists in a population already at elevated risk of complications. While diabetes care has successfully operationalized pharmacological and behavioral risk reduction across multiple domains, tobacco treatment remains marginal, fragmented, and weakly institutionalized.&lt;/p&gt;&lt;p&gt;Tobacco smoking remains common among adults living with T2D worldwide. A systematic review and meta-analysis spanning 74 studies across 33 countries, including approximately 3.2 million participants, estimated a global mean tobacco use prevalence of 20.8% among people with T2D [&lt;span&gt;5&lt;/span&gt;]. Prevalence varied substantially by region (Figure 1). Estimates were highest in East Asia and the Pacific (28.0%), followed by South Asia (26.0%), Latin America and the Caribbean (21.9%), the Middle East and North Africa (19.2%), and North America (19.2%). Europe and Central Asia reported a lower prevalence of 16.6% [&lt;span&gt;5&lt;/span&gt;]. A separate meta-analysis from Africa estimated an overall active smoking prevalence among people with diabetes of 12.9%, with notable subregional variation: 21.3% in North Africa compared with 10.3% in Sub-Saharan Africa [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Importantly, these estimates are broadly comparable to those observed in adults without diabetes. In the 33 studies within the same meta-analysis that included a non-diabetic comparator group, pooled to","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147621338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Debate on the Dietary Guidelines for Americans (2025–2030) and Implications for China's Nutritional Policy","authors":"Junshi Chen","doi":"10.1111/1753-0407.70218","DOIUrl":"10.1111/1753-0407.70218","url":null,"abstract":"&lt;p&gt;On January 7, 2026, the U.S. Department of Health and Human Services and the U.S. Department of Agriculture jointly released the Dietary Guidelines for Americans (DGA, 2025–2030) [&lt;span&gt;1&lt;/span&gt;]. Since its publication, the document has sparked considerable media attention and scientific debate, particularly regarding its departure from certain long-standing visual and conceptual models—the “MyPyramid” [&lt;span&gt;2&lt;/span&gt;] and “MyPlate” [&lt;span&gt;3&lt;/span&gt;] (Figure 1).&lt;/p&gt;&lt;p&gt;This commentary aims to interpret the key changes introduced in the DGA (2025–2030) and discuss their relevance and implications for China's nutrition policy and the dietary guidelines for Chinese people. The central question is: Should these American guidelines influence eating habits and public health strategies in China?&lt;/p&gt;&lt;p&gt;At its core, the DGA (2025–2030) does not represent a radical departure from earlier editions. The overarching objective—to prevent the increase of obesity and other non-communicable diseases (NCDs)—remains unchanged. Similarly, most foundational recommendations are consistent [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;These changes have been challenged by several U.S.-based scientific bodies. The American Heart Association (AHA) and the American Society for Nutrition (ASN) have raised substantial concerns. Criticisms focus on the evidence strength for certain recommendations (particularly those mentioned above), potential industry influence, and the practical feasibility of avoiding all processed foods and sweeteners.&lt;/p&gt;&lt;p&gt;For example, AHA commented: “We are concerned that recommendations regarding salt seasoning and red meat consumption could inadvertently lead consumers to exceed recommended limits for sodium and saturated fats, which are primary drivers of cardiovascular disease. While the guidelines highlight whole-fat dairy, the Heart Association encourages consumption of low-fat and fat-free dairy products, which can be beneficial to heart health.” [&lt;span&gt;6&lt;/span&gt;] Similarly, ASN stated: “ASN is concerned that departing from the established scientific review process undermines confidence in the DGAs and nutrition science, contributes to confusion and distrust, and obscures the opportunity for meaningful scientific discourse.” [&lt;span&gt;7&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Prof. Cristina Palacios, a member of the Dietary Guidelines Advisory Committee (DGAC) (2022–2024), noted that “most of the Committee's recommendations were ignored in developing the latest dietary guidelines” [&lt;span&gt;8&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;To answer this, one must consider the current dietary pattern and nutritional status of the Chinese population in the context of NCD prevention, with reference to the Dietary Guidelines for Chinese People (DGCP, 2022) [&lt;span&gt;9&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Over the past three decades (1982–2020), China's dietary patterns have shifted dramatically from traditional plant-based diets toward Westernized patterns [&lt;span&gt;10-14&lt;/span&gt;]. Average dietary energy and carbohydrate intakes decreased significantly from 2","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147615599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain Modulation and Central Sensitization in Painful Diabetic Peripheral Neuropathy: Updated Narrative Review and Future Directions","authors":"Di Ye,&nbsp;Timothy J. Fairchild,&nbsp;Lechi Vo,&nbsp;Peter D. Drummond","doi":"10.1111/1753-0407.70223","DOIUrl":"10.1111/1753-0407.70223","url":null,"abstract":"<p>Painful diabetic peripheral neuropathy (DPN) arises from damage to sensory neurons, manifesting in persistent pain. Progressive nerve degeneration can result in sensory loss and, in severe cases, amputation, exacerbating emotional distress and diminishing quality of life. Continuing investigation into DPN mechanisms is essential for advancing effective pain management. Our previous narrative review identified oxidative stress and central sensitization as key pathways linking hyperglycemia to nerve injury and pain. The present review provides an updated synthesis of evidence in this area. The original PubMed search term was expanded to include metabolic syndrome and pain modulation, and studies published between September 2021 and February 2026 were examined. The current findings reinforce earlier conclusions that alterations within the central nervous system and central sensitization are prominent features of painful DPN. Emerging evidence suggests that metabolic syndrome such as overweight may impair pain modulation in individuals with or without risk of diabetes. Future research should determine whether impaired pain modulation can serve as an early indicator of DPN, enabling earlier intervention. Clarifying these mechanisms may also help explain why medications that restore pain modulation show therapeutic promise for this complex chronic pain condition.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147615631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subgroups of Prediabetes and the Risk of Cardiometabolic Multimorbidity in Chinese Adults: A Prospective Cohort Study.","authors":"Yan Liu, Miao He, Yu Liu, Zilin Sun, Shanhu Qiu","doi":"10.1111/1753-0407.70224","DOIUrl":"10.1111/1753-0407.70224","url":null,"abstract":"","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":"e70224"},"PeriodicalIF":5.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atherogenic Index of Plasma Predicts the Onset and Progression of Cardio-Renal-Metabolic Multimorbidity: Evidence From a Nationwide Prospective Cohort Study.","authors":"Jijie Jin, Fei Wang, Shengzhang Chen, Jiaxin Shao, Binyan Chen, Xiufang Lin","doi":"10.1111/1753-0407.70227","DOIUrl":"10.1111/1753-0407.70227","url":null,"abstract":"<p><strong>Background: </strong>Cardio-renal-metabolic (CRM) multimorbidity, defined by the co-occurrence of cardiovascular disease (CVD), chronic kidney disease (CKD), and type 2 diabetes (T2DM), poses a growing burden for multimorbidity management. The atherogenic index of plasma (AIP), a lipid-based marker of insulin resistance, may help predict CRM progression, but its prognostic value remains unclear.</p><p><strong>Methods: </strong>We used data from 5805 adults free of CRM at baseline in the China Health and Retirement Longitudinal Study. AIP was calculated as log₁₀[triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C)]. CRM onset was defined as incident CVD, T2DM, or CKD. Multistate models captured transitions from no disease to single, dual, and triple CRM states. Cox regression and time-dependent receiver operating characteristic (ROC) curves were used to assess associations and predictive performance.</p><p><strong>Results: </strong>AIP showed a clear dose-response relationship with CRM progression. Each 1-standard deviation (SD) increase in AIP was associated with higher risks of single (HR 1.17, 95% CI 1.13-1.22), dual (HR 1.31, 95% CI 1.21-1.41), and triple CRM (HR 1.57, 95% CI 1.27-1.94) diseases. Strong associations were observed for new-onset T2DM and stroke, but not CKD. AIP yielded the highest discrimination for triple CRM (5-year area under the curve [AUC] = 0.710). Multistate modeling showed each 1-SD increase in AIP raised the hazard of transitioning from single to dual CRM by 14% and from dual to triple by 31%.</p><p><strong>Conclusions: </strong>AIP is an independent, simple, and low-cost predictor of CRM onset and progression, with potential utility for early risk stratification and prevention.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":"e70227"},"PeriodicalIF":5.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13104600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147758354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing the China-SCO Cooperation Center for Metabolic Diseases to Build a Prevention and Control System for Metabolic Disorders, Advancing the Global Community of Shared Future.","authors":"Guang Ning","doi":"10.1111/1753-0407.70211","DOIUrl":"10.1111/1753-0407.70211","url":null,"abstract":"","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":"e70211"},"PeriodicalIF":3.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There Any Difference in Preferences Between Patients and Physicians? Evidence From Anti-Hyperglycemic Medications Choices for Type 2 Diabetes.","authors":"Yuliang Xiang, Liu Liu, Jing Liu, Xiong Ke, Yanfeng Ren, Shiyi Bao, Fuming Li, Shimeng Liu, Yingyao Chen","doi":"10.1111/1753-0407.70220","DOIUrl":"10.1111/1753-0407.70220","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to explore differences in preferences between Chinese patients with type 2 diabetes mellitus (T2D) and physicians when selecting anti-hyperglycemic medications.</p><p><strong>Materials and methods: </strong>We conducted a discrete choice experiment (DCE) involving 1784 patients (face-to-face surveys) and 168 physicians (online questionnaires) across eastern, central, and western China. Seven treatment attributes were assessed: HbA1c reduction, hypoglycemia risk, cardiovascular benefits, gastrointestinal adverse events, weight change, mode of administration, and monthly out-of-pocket cost. Preference heterogeneity was explored using latent class model.</p><p><strong>Results: </strong>Patients placed the greatest importance on monthly out-of-pocket cost, treatment efficacy, and hypoglycemia risk, whereas physicians prioritized hypoglycemia risk, cardiovascular benefits, and treatment efficacy. Notably, physicians tended to overestimate patients' willingness to pay for treatment benefits. Specifically, patients were willing to pay 277 CNY (39 USD) for cardiovascular benefits, whereas physicians estimated that patients would be willing to pay 864 CNY (121 USD). Latent class analysis identified substantial heterogeneity in both groups. In particular, the largest patient subgroup was strongly cost-sensitive, with preferences driven primarily by financial burden, whereas no directly corresponding physician subgroup was observed.</p><p><strong>Conclusion: </strong>Patients and physicians differ in how they prioritize diabetes medication attributes, especially regarding efficacy, cardiovascular benefit, and cost. Shared decision-making should account for these differences to support value-concordant, patient-centered diabetes care.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 4","pages":"e70220"},"PeriodicalIF":5.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13083033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}